DK3297649T5 - Peptid-oligonukleotid-konjugater - Google Patents
Peptid-oligonukleotid-konjugater Download PDFInfo
- Publication number
- DK3297649T5 DK3297649T5 DK16797300.7T DK16797300T DK3297649T5 DK 3297649 T5 DK3297649 T5 DK 3297649T5 DK 16797300 T DK16797300 T DK 16797300T DK 3297649 T5 DK3297649 T5 DK 3297649T5
- Authority
- DK
- Denmark
- Prior art keywords
- peptide
- oligonucleotide conjugates
- conjugates
- oligonucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562163960P | 2015-05-19 | 2015-05-19 | |
| US201662337536P | 2016-05-17 | 2016-05-17 | |
| PCT/US2016/033276 WO2016187425A1 (en) | 2015-05-19 | 2016-05-19 | Peptide oligonucleotide conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3297649T3 DK3297649T3 (da) | 2023-12-18 |
| DK3297649T5 true DK3297649T5 (da) | 2024-10-07 |
Family
ID=57320822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16797300.7T DK3297649T5 (da) | 2015-05-19 | 2016-05-19 | Peptid-oligonukleotid-konjugater |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10675356B2 (da) |
| EP (2) | EP4306538A3 (da) |
| JP (2) | JP6954843B2 (da) |
| KR (2) | KR20240035901A (da) |
| CN (2) | CN107921092B (da) |
| AU (1) | AU2016264471B2 (da) |
| BR (1) | BR112017024929A2 (da) |
| CA (1) | CA2986228A1 (da) |
| DK (1) | DK3297649T5 (da) |
| ES (1) | ES2964695T3 (da) |
| FI (1) | FI3297649T3 (da) |
| HK (1) | HK1252759A1 (da) |
| HR (1) | HRP20231431T1 (da) |
| IL (1) | IL255655B (da) |
| MA (1) | MA42134A (da) |
| MX (1) | MX2017014806A (da) |
| NZ (2) | NZ776280A (da) |
| WO (1) | WO2016187425A1 (da) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42134A (fr) * | 2015-05-19 | 2018-03-28 | Sarepta Therapeutics Inc | Conjugués peptides/oligonucléotides |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| CN109757108A (zh) | 2016-07-05 | 2019-05-14 | 比奥马林技术公司 | 具有治疗遗传疾病的改善特征的包含双环支架部分的前体mRNA剪接转换或调节寡核苷酸 |
| CA3049424A1 (en) * | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| KR102279333B1 (ko) | 2017-03-07 | 2021-07-20 | 주식회사 만도 | 차량의 디스플레이 시스템 및 이의 구동 방법 |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB2580569B (en) * | 2017-06-28 | 2021-08-18 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| MX2020003130A (es) * | 2017-09-22 | 2020-09-25 | Avidity Biosciences Inc | Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos. |
| KR20200060496A (ko) | 2017-10-04 | 2020-05-29 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 그의 용도 |
| WO2019079367A1 (en) * | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | OLIGONUCLEOTIDE CONJUGATES-BICYCLIC PEPTIDES |
| CN111902148B (zh) | 2017-12-06 | 2024-07-05 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| EP3829597A4 (en) * | 2018-07-30 | 2022-05-18 | Sarepta Therapeutics, Inc. | TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION |
| EA202190416A1 (ru) | 2018-08-02 | 2021-06-23 | Дайн Терапьютикс, Инк. | Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| WO2020247782A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| CN114375297A (zh) | 2019-06-06 | 2022-04-19 | 艾维迪提生物科学公司 | Una亚酰胺及其用途 |
| JPWO2021132591A1 (da) | 2019-12-26 | 2021-07-01 | ||
| CN115210376A (zh) | 2020-02-28 | 2022-10-18 | 日本新药株式会社 | 诱导外显子51的跳读的反义核酸 |
| CN115666589A (zh) | 2020-03-19 | 2023-01-31 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| WO2022212886A1 (en) * | 2021-04-02 | 2022-10-06 | Avidity Biosciences, Inc. | Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping |
| KR20240024176A (ko) | 2021-06-23 | 2024-02-23 | 니뽄 신야쿠 가부시키가이샤 | 안티센스 올리고머의 조합 |
| US20240316093A1 (en) | 2021-07-08 | 2024-09-26 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
| JPWO2023282344A1 (da) | 2021-07-08 | 2023-01-12 | ||
| EP4368187A1 (en) | 2021-07-08 | 2024-05-15 | Nippon Shinyaku Co., Ltd. | Precipitation suppressing agent |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP4366784A1 (en) | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CA3226001A1 (en) | 2021-07-16 | 2023-01-19 | Anton Jan Van Zonneveld | Oligonucleotide for inhibiting quaking activity |
| AU2022345098A1 (en) | 2021-09-16 | 2024-04-04 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| JPWO2023171804A1 (da) | 2022-03-10 | 2023-09-14 | ||
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| AU2023254846A1 (en) | 2022-04-15 | 2024-10-10 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| KR20250017212A (ko) | 2022-05-06 | 2025-02-04 | 아카데미슈 지켄후이스 라이덴 (에이치.오.디.엔. 룸씨) | 올리고뉴클레오타이드 |
| WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
| WO2025007907A1 (zh) * | 2023-07-04 | 2025-01-09 | 大睿生物 | 包含肽的寡核苷酸递送配体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| EP0216860B1 (en) | 1985-03-15 | 1992-10-28 | SUMMERTON, James | Stereoregular polynucleotide-binding polymers |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| BR122019021332A8 (pt) | 2007-11-15 | 2022-12-06 | Avi Biopharma Inc | Processo de síntese de oligômeros de morfolino |
| WO2010048568A1 (en) * | 2008-10-23 | 2010-04-29 | Targeted Growth, Inc. | Modified photosynthetic microorganisms for producing triglycerides |
| CN102203253B (zh) * | 2008-10-24 | 2016-04-06 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CA2781618A1 (en) * | 2009-11-25 | 2011-06-03 | Elitech Holding B.V. | Minor groove binder (mgb)-oligonucleotide mirna antagonists |
| US9173895B2 (en) * | 2009-12-16 | 2015-11-03 | Curna, Inc. | Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 |
| SI2623507T1 (sl) | 2010-09-30 | 2017-04-26 | Nippon Shinyaku Co.,Ltd. | Derivati morfolino-nukleinske kisline |
| AU2012246822B2 (en) | 2011-04-22 | 2017-05-25 | Biomarin Technologies B.V. | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1) |
| KR102229650B1 (ko) | 2011-05-05 | 2021-03-19 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
| EP3858847A1 (en) * | 2011-11-30 | 2021-08-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
| PT2788487T (pt) * | 2011-12-08 | 2018-07-03 | Sarepta Therapeutics Inc | Análogos de oligonucleótido visando lmna humano |
| BR112014023347A2 (pt) * | 2012-03-20 | 2017-07-18 | Sarepta Therapeutics Inc | conjugados de ácido borônico de análogos oligonucleotídeos |
| BR112014033004B1 (pt) * | 2012-07-03 | 2021-10-19 | Biomarin Technologies B.V. | Oligonucleotídeo para tratamento de pacientes com distrofia muscular |
| EP2900821B1 (en) * | 2012-09-25 | 2020-04-01 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| EA201591792A1 (ru) | 2013-03-15 | 2016-02-29 | Сарепта Терапьютикс, Инк. | Улучшенные композиции для лечения мышечной дистрофии |
| US20180216111A1 (en) | 2015-02-27 | 2018-08-02 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| MA42134A (fr) * | 2015-05-19 | 2018-03-28 | Sarepta Therapeutics Inc | Conjugués peptides/oligonucléotides |
-
2016
- 2016-05-19 MA MA042134A patent/MA42134A/fr unknown
- 2016-05-19 NZ NZ776280A patent/NZ776280A/en unknown
- 2016-05-19 KR KR1020247007058A patent/KR20240035901A/ko active Pending
- 2016-05-19 KR KR1020177035825A patent/KR102644053B1/ko active Active
- 2016-05-19 HR HRP20231431TT patent/HRP20231431T1/hr unknown
- 2016-05-19 AU AU2016264471A patent/AU2016264471B2/en active Active
- 2016-05-19 FI FIEP16797300.7T patent/FI3297649T3/fi active
- 2016-05-19 EP EP23195508.9A patent/EP4306538A3/en active Pending
- 2016-05-19 CN CN201680041867.9A patent/CN107921092B/zh active Active
- 2016-05-19 CA CA2986228A patent/CA2986228A1/en active Pending
- 2016-05-19 WO PCT/US2016/033276 patent/WO2016187425A1/en active Application Filing
- 2016-05-19 EP EP16797300.7A patent/EP3297649B1/en active Active
- 2016-05-19 ES ES16797300T patent/ES2964695T3/es active Active
- 2016-05-19 NZ NZ737757A patent/NZ737757A/en unknown
- 2016-05-19 MX MX2017014806A patent/MX2017014806A/es unknown
- 2016-05-19 CN CN202210279461.1A patent/CN114681621B/zh active Active
- 2016-05-19 BR BR112017024929-4A patent/BR112017024929A2/pt active Search and Examination
- 2016-05-19 US US15/574,734 patent/US10675356B2/en active Active
- 2016-05-19 JP JP2017560238A patent/JP6954843B2/ja active Active
- 2016-05-19 DK DK16797300.7T patent/DK3297649T5/da active
-
2017
- 2017-11-14 IL IL255655A patent/IL255655B/en unknown
-
2018
- 2018-09-19 HK HK18112084.2A patent/HK1252759A1/zh unknown
-
2020
- 2020-04-28 US US16/860,292 patent/US11097011B2/en active Active
- 2020-11-05 JP JP2020185083A patent/JP2021011505A/ja active Pending
-
2021
- 2021-08-16 US US17/403,403 patent/US11672871B2/en active Active
-
2023
- 2023-04-06 US US18/296,697 patent/US12239715B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3297649T5 (da) | Peptid-oligonukleotid-konjugater | |
| LT3525830T (lt) | Pirolbenzodiazepino konjugatai | |
| EP3484518C0 (en) | Antibody adjuvant conjugates | |
| DK3268047T3 (da) | Amatoxin/antistof-konjugater | |
| DK3579883T3 (da) | Pyrrolobenzodiazepin-antistofkonjugater | |
| DK3283625T3 (da) | Nukleasemedieret genomeditering | |
| EP3360001A4 (en) | HEAD-MOUNTED DISPLAY DEVICE | |
| DK3119885T3 (da) | Antistof-fynomer-konjugater | |
| LT3544636T (lt) | Pirolobenzodiazepino-antikūno konjugatai | |
| DK3137114T3 (da) | Anti-PTK7-antistof-lægemiddelkonjugater | |
| EP3316375A4 (en) | Redox flow cell | |
| DK3277719T3 (da) | Polypeptider | |
| DK3305788T3 (da) | Janus-kinase-hæmmer | |
| FR3039337B1 (fr) | Motoreducteur compact | |
| DK3148591T3 (da) | Nanopartikel-lægemiddelkonjugater | |
| EP3337164A4 (en) | HEAD-MOUNTED DISPLAY | |
| DK3612537T3 (da) | Pyrrolobenzodiazepinkonjugater | |
| DK3270930T3 (da) | Præeklampsi | |
| EP3355931C0 (en) | PROTEIN CONJUGATES | |
| KR20180084876A (ko) | 내플라즈마성 부재 | |
| LT3371168T (lt) | Indolin-2-ono dariniai | |
| EP3309163A4 (en) | SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE | |
| DK3292136T3 (da) | Penicillin-g-acylaser | |
| DK3544634T3 (da) | MET-antistof-lægemiddelkonjugater | |
| DE112015006486A5 (de) | Inkubationsrinne |